{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:24:53Z","timestamp":1777685093612,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2019,2,13]]},"DOI":"10.3233\/jhd-180328","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T22:42:00Z","timestamp":1548196920000},"page":"79-85","source":"Crossref","is-referenced-by-count":9,"title":["Attitudes of Potential Participants Towards Molecular Therapy Trials in Huntington\u2019s Disease"],"prefix":"10.1177","volume":"8","author":[{"given":"Tanya M.","family":"Bardakjian","sequence":"first","affiliation":[{"name":"Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaylee Faulkner","family":"Naczi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Gonzalez-Alegre","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"},{"name":"Raymond G. Perelman Center for Cellular & Molecular Therapeutics, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"4","key":"10.3233\/JHD-180328_ref1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: Natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JHD-180328_ref2","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.3233\/JHD-180328_ref3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in Huntington\u2019s disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"10.3233\/JHD-180328_ref4","first-page":"139","article-title":"Public attitudes to human gene therapy: A Pilot study in Wales","volume":"6","author":"Iredale","year":"2003","journal-title":"Community Genet"},{"issue":"8","key":"10.3233\/JHD-180328_ref5","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s12325-017-0587-7","article-title":"Patient perspectives on gene transfer therapy for sickle cell disease","volume":"34","author":"Strong","year":"2017","journal-title":"Adv Ther"},{"key":"10.3233\/JHD-180328_ref6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.omtm.2017.05.008","article-title":"Public attitudes toward gene therapy in China","volume":"6","author":"Wang","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"9","key":"10.3233\/JHD-180328_ref7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.socscimed.2004.08.058","article-title":"How acceptable are innovative health-care technologies? A Survey of public beliefs and attitudes in England and Wales","volume":"60","author":"Calnan","year":"2005","journal-title":"Soc Sci Med"},{"issue":"4","key":"10.3233\/JHD-180328_ref8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/mt.2012.230","article-title":"Gene therapy researchers\u2019 assessments of risks and perceptions of risk acceptability in clinical trials","volume":"21","author":"Deakin","year":"2013","journal-title":"Mol Ther"},{"issue":"19-20","key":"10.3233\/JHD-180328_ref9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.drudis.2011.06.008","article-title":"European attitudes to gene therapy and pharmacogenetics","volume":"16","author":"Hudson","year":"2011","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.3233\/JHD-180328_ref10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1089\/hum.1995.6.6-791","article-title":"International perceptions and approval of gene therapy","volume":"6","author":"Macer","year":"1995","journal-title":"Hum Gene Ther"},{"issue":"8","key":"10.3233\/JHD-180328_ref11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1089\/hum.2014.030","article-title":"Prevailing public perceptions of the ethics of gene therapy","volume":"25","author":"Robillard","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.3233\/JHD-180328_ref12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.3233\/JHD-180328_ref13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/JHD-189001","article-title":"Huntington\u2019s disease clinical trials corner: February 2018","volume":"7","author":"Rodrigues","year":"2018","journal-title":"J Huntingtons Dis"},{"issue":"2","key":"10.3233\/JHD-180328_ref14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/nat.2018.0720","article-title":"Dose-dependent lowering of mutant huntingtin using antisense oligonucleotides in Huntington disease patients","volume":"28","author":"van Roon-Mom","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"10.3233\/JHD-180328_ref15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s13311-014-0299-5","article-title":"Gene therapy for the nervous system: Challenges and new strategies","volume":"11","author":"Maguire","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JHD-180328_ref16","doi-asserted-by":"crossref","unstructured":"Dunbar CE , High KA , Joung JK , Kohn DB , Ozawa K , Sadelain M Gene therapy comes of age. Science. 2018;359(6372).","DOI":"10.1126\/science.aan4672"},{"issue":"6","key":"10.3233\/JHD-180328_ref17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/hum.2017.199","article-title":"Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of Huntington\u2019s disease","volume":"29","author":"Pfister","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.3233\/JHD-180328_ref18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-1-4939-3271-9_29","article-title":"Stereotaxic surgical targeting of the nonhuman primate caudate and putamen: Gene therapy for Huntington\u2019s disease","volume":"1382","author":"McBride","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"12","key":"10.3233\/JHD-180328_ref19","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol Ther"},{"key":"10.3233\/JHD-180328_ref20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","article-title":"Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease","volume":"76","author":"Southwell","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.3233\/JHD-180328_ref21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jval.2014.02.012","article-title":"Patient-centeredness in the design of clinical trials","volume":"17","author":"Mullins","year":"2014","journal-title":"Value Health"},{"issue":"5","key":"10.3233\/JHD-180328_ref22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40271-017-0257-5","article-title":"Inaugural conference on incorporating patient-reported outcomes and patient preference information into clinical research, clinical care, and risk-benefit assessments for neurodegenerative diseases","volume":"10","author":"Purks","year":"2017","journal-title":"Patient"},{"key":"10.3233\/JHD-180328_ref23","doi-asserted-by":"crossref","first-page":"g368","DOI":"10.1136\/bmj.g368","article-title":"Subjects no more: What happens when trial participants realize they hold the power?","volume":"348","author":"Wicks","year":"2014","journal-title":"BMJ"},{"issue":"11","key":"10.3233\/JHD-180328_ref24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.gt.3301752","article-title":"Gene therapy and the public: A Matter of trust","volume":"9","author":"Gottweis","year":"2002","journal-title":"Gene Ther"},{"issue":"11","key":"10.3233\/JHD-180328_ref25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/GIM.0b013e318159a344","article-title":"Assessing hypothetical scenario methodology in genetic susceptibility testing analog studies: A Quantitative review","volume":"9","author":"Persky","year":"2007","journal-title":"Genet Med"},{"issue":"1","key":"10.3233\/JHD-180328_ref26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/gte.1999.3.139","article-title":"Public understanding of genetics and Alzheimer disease","volume":"3","author":"Stockdale","year":"1999","journal-title":"Genet Test"},{"issue":"6","key":"10.3233\/JHD-180328_ref27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1191\/1740774504cn053oa","article-title":"The Effects of an open design on trial participant recruitment, compliance and retention\u2014a randomized controlled trial comparison with a blinded, placebo-controlled design","volume":"1","author":"Avenell","year":"2004","journal-title":"Clin Trials"},{"issue":"7191","key":"10.3233\/JHD-180328_ref28","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/bmj.318.7191.1114","article-title":"Is recruitment more difficult with a placebo arm in randomised controlled trials? A Quasirandomised, interview based study","volume":"318","author":"Welton","year":"1999","journal-title":"BMJ"},{"issue":"3","key":"10.3233\/JHD-180328_ref29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jalz.2012.03.001","article-title":"Risk disclosure and preclinical Alzheimer\u2019s disease clinical trial enrollment","volume":"9","author":"Grill","year":"2013","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-180328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:50:44Z","timestamp":1777452644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-180328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":29,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jhd-180328","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]}}}